Formulation and In Vitro Evaluation of PLGA Nanoparticles of Temozolomide

In this study, we formulated and investigated the effects of Temozolomide (TM)/Poly (lactide-co-glycolide) (PLGA) nanoparticles on the behaviour of C6 glioma cells. The nanoparticles were fabricated by the emulsifying solvent evaporation, and they were characterized by using X-Ray diffraction, scanning electron microscopy (SEM), transmission electron microscopy (TEM). Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) showed that such nanoparticles had a smooth surface and a spherical geometry. Powder X-ray diffraction (XRD) results indicated that TM trapped in the nanoparticles existed in an amorphous or disordered-crystalline status in the polymer matrix. The release profiles of Temozolomide from nanoparticles resulted in biphasic patterns. After an initial burst, a continuous drug release was observed for up to 1 month. Finally, a cytotoxicity test was performed using Glioma C6 cancer cells to investigate the cytotoxicity of Temozolomide delivered from PLGA nanoparticles. It has been found that the cytotoxicity of Temozolomide to Glioma C6 cancer cells is enhanced when TM is delivered from PLGA polymeric carrier and while Temozolomide powder shows activity only up to 12 hours, where as Temozolomide loaded PLGA nanoparticles shows cytotoxicity in much more enhanced way.